A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- RANDOMIZED · PARALLEL · PREVENTION · NONE
- Evidence population
- Human clinical study registration
- Participants
- 60
- Population
- ALL · 60 Years
- Duration
- 2026-05-01 to 2026-07-01
- Intervention
- Sirolimus (RAPAMUNE); Influenza vaccine (Sequiris Fluad Quad); RSV vaccine (Pfizer Abrysvo)
- Comparator
- Control
- Outcomes measured
- Vaccine-specific functional T cell memory — Six weeks post vaccination; Cellular immune response to vaccination — Six weeks post vaccination; Vaccine-specific humoral immune response — Six week post vaccination; Incidence of infection post-vaccination — Twelve months post vaccination; Incidence of Sirolimus (Rapamycin) Treatment-Emergent Adverse Events [Safety and Tolerability] — Six week post vaccinat…; Incidence of Immunization Treatment-Emergent Adverse Events [Safety and Tolerability] — Six weeks post vaccination; Quality of life questionnaire — Six weeks post-vaccination; Circulating IL-1β analysis — Three weeks after commencement of sirolimus (after administration of final dose of sirolim…; Circulating IFN-α2 analysis — Three weeks after commencement of sirolimus (after administration of final dose of siroli…; Circulating IFN-γ analysis — Three weeks after commencement of sirolimus (after administration of final dose of sirolim…; Circulating TNF-α analysis — Three weeks after commencement of sirolimus (after administration of final dose of sirolim…; Circulating MCP-1 analysis — Three weeks after commencement of sirolimus (after administration of final dose of sirolim…; Circulating IL-6 analysis — Three weeks after commencement of sirolimus (after administration of final dose of sirolimu…; Circulating CXCL8 (IL-8) — Three weeks after commencement of sirolimus (after administration of final dose of sirolimus); Circulating IL-10 analysis — Three weeks after commencement of sirolimus (after administration of final dose of sirolim…; Circulating IL-12p70 analysis — Three weeks after commencement of sirolimus (after administration of final dose of siro…; Circulating IL-17A analysis — Three weeks after commencement of sirolimus (after administration of final dose of siroli…; Circulating IL-18 analysis — Three weeks after commencement of sirolimus (after administration of final dose of sirolim…; Circulating IL-23 analysis — Three weeks after commencement of sirolimus (after administration of final dose of sirolim…; Circulating IL-33 analysis — Three weeks after commencement of sirolimus (after administration of final dose of sirolim…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Rapamycin · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Source terminology supplies ageing or longevity context.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.